Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,113,134
  • Shares Outstanding, K 122,492
  • Annual Sales, $ 196,540 K
  • Annual Income, $ -140,040 K
  • EBIT $ -38 M
  • EBITDA $ -43 M
  • 60-Month Beta 1.70
  • Price/Sales 10.10
  • Price/Cash Flow N/A
  • Price/Book 21.66

Options Overview Details

View History
  • Implied Volatility 75.69% (+5.12%)
  • Historical Volatility 47.01%
  • IV Percentile 65%
  • IV Rank 37.54%
  • IV High 116.97% on 08/01/25
  • IV Low 50.87% on 12/30/25
  • Expected Move (DTE 27) 3.65 (14.35%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 2,446
  • Volume Avg (30-Day) 857
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 12,752
  • Open Int (30-Day) 9,084
  • Expected Range 21.77 to 29.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.03
  • Number of Estimates 3
  • High Estimate 0.10
  • Low Estimate -0.02
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.50 +3.73%
on 02/02/26
28.12 -9.62%
on 02/20/26
-0.45 (-1.76%)
since 01/20/26
3-Month
24.50 +3.73%
on 02/02/26
31.77 -20.00%
on 12/08/25
-1.91 (-7.01%)
since 11/20/25
52-Week
11.75 +116.30%
on 02/25/25
31.77 -20.00%
on 12/08/25
+12.00 (+89.38%)
since 02/20/25

Most Recent Stories

More News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 25.42 (-9.07%)
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis

58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4 Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a safety...

ARQT : 25.42 (-9.07%)
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa

WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 25.42 (-9.07%)
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ET Arcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February...

ARQT : 25.42 (-9.07%)
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions

Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effects Nearly 8 in 10 adults...

ARQT : 25.42 (-9.07%)
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

Continued strong growth of ZORYVE ® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 million Advancement of ZORYVE indication-expansion strategy beginning with ongoing...

ARQT : 25.42 (-9.07%)
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 25.42 (-9.07%)
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026 If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children...

ARQT : 25.42 (-9.07%)
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA approved...

ARQT : 25.42 (-9.07%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 25.42 (-9.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 30.54
2nd Resistance Point 29.33
1st Resistance Point 27.37
Last Price 25.42
1st Support Level 24.20
2nd Support Level 22.99
3rd Support Level 21.03

See More

52-Week High 31.77
Last Price 25.42
Fibonacci 61.8% 24.12
Fibonacci 50% 21.76
Fibonacci 38.2% 19.40
52-Week Low 11.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar